Prolactin excess: Treatment and toxicity

Mary P. Gillam, Hugo Fideleff, Hugo R. Boquete, Mark E Molitch*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Dopamine agonists provide highly effective therapy for the treatment of hyperprolactinemia. As a result of their efficacy and tolerability, these agents are considered to be the initial therapy of choice in children, adolescents and adults with idiopathic hyperprolactinemia and prolactinomas. The four dopamine agonists, bromocriptine, pergolide, cabergoline and quinagolide, share a similar mechanism of action and side effect profile. Although studies of cabergoline have demonstrated the highest treatment efficacy and tolerability, all four of these agents are safe, effective and tolerable in children and adolescents. When fertility is desired, bromocriptine is generally preferable, but cabergoline is also likely safe; pergolide and quinagolide should not be used in this setting.

Original languageEnglish (US)
Pages (from-to)108-114
Number of pages7
JournalPediatric Endocrinology Reviews
Issue numberSUPPL. 1
StatePublished - Nov 1 2004


  • Adolescent
  • Bromocriptine
  • Cabergoline
  • Hyperprolactinemia
  • Pediatric
  • Pergolide
  • Prolactinoma
  • Quinogolide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine


Dive into the research topics of 'Prolactin excess: Treatment and toxicity'. Together they form a unique fingerprint.

Cite this